An evidence-based clinical primer on semaglutide, tirzepatide, and the GLP-1 class. What the trials actually showed, what the peer-reviewed concerns are, and the root-cause metabolic alternative.
GLP-1 medications — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and the broader class — have changed weight-loss medicine. Trials show meaningful reductions in body weight. Patients see clinical results. The category is one of the most prescribed pharmaceutical interventions in the United States.
It is also a category with documented adverse-event profiles, a boxed warning, lean-mass concerns, and an open question about what happens when the medication stops. Both of these things are true at once. This article is for patients trying to make an informed decision — not patients looking to be sold for or against.
GLP-1 (glucagon-like peptide-1) is a naturally-occurring incretin hormone released by the gut after eating. It signals the pancreas to release insulin, slows gastric emptying, and acts on satiety centers in the brain. The medications in the GLP-1 class are receptor agonists — engineered peptides that bind the GLP-1 receptor and produce these effects far more strongly and persistently than the body's own GLP-1.
The combined result is reduced appetite, slower digestion, improved glucose control, and over time, substantial weight loss. The mechanism is well-established (Knudsen & Lau, Frontiers in Endocrinology, 20191). The trials behind FDA approval show average weight reductions of 12-21% of body weight depending on the agent and duration.
These numbers are real. They are also the reason the category has become as large as it has.
The same literature that supports the efficacy of GLP-1 medications also documents a set of clinical concerns. None of these are fringe positions — they are published findings from major journals, FDA labels, or the trial datasets themselves. A patient considering GLP-1 therapy should understand them.
A 2023 JAMA analysis of GLP-1 weight-loss prescriptions found significantly elevated risks of gastrointestinal adverse events versus comparator weight-loss medications — including an approximately fourfold increase in biliary disease, a more than threefold increase in pancreatitis, and a markedly elevated risk of bowel obstruction and gastroparesis (Sodhi et al., JAMA, 20232). Gastroparesis — delayed gastric emptying — can persist after medication discontinuation in some patients.
2. Sodhi M, et al. "Risk of Gastrointestinal Adverse Events Associated With GLP-1 Receptor Agonists for Weight Loss." JAMA. 2023;330(18):1795-1797. PubMed 37796527Semaglutide and tirzepatide both carry an FDA boxed warning regarding the risk of thyroid C-cell tumors, including medullary thyroid carcinoma, based on rodent studies. The human relevance of these findings has not been fully determined. Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) are contraindicated for the class. This is a labeled warning from the prescribing information — not editorial commentary.
FDA prescribing information, Wegovy and Zepbound product labels. FDA Label (semaglutide)The weight loss produced by GLP-1 medications is not exclusively fat. Body composition data from the STEP trials (semaglutide) and SURMOUNT trials (tirzepatide) document meaningful reductions in lean body mass alongside fat-mass reductions — estimated in the range of 25-40% of total weight loss being lean tissue, depending on the analysis. For older patients, particularly post-menopausal women and men with established sarcopenia risk, this matters. Muscle is metabolically active tissue; losing it accelerates the very metabolic dysfunction patients are trying to address.
3. Ida S, et al. "Effects of antidiabetic drugs on muscle mass in type 2 diabetes mellitus." Current Diabetes Reviews. 2021;17(3):293-303. PubMed 32619173The STEP 1 trial extension found that participants who discontinued semaglutide regained, on average, about two-thirds of their lost weight within one year of stopping. Cardiometabolic improvements reverted in parallel. The implication: for many patients, GLP-1 therapy may not be a finite course but a chronic medication — a meaningful consideration in any informed-consent conversation.
4. Wilding JPH, et al. "Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension." Diabetes, Obesity and Metabolism. 2022;24(8):1553-1564. PubMed 35441470GLP-1 receptor agonists have been in use for type 2 diabetes for over a decade, but the higher-dose weight-loss indications are newer, and the off-label compounded versions newer still. Beyond the initial 68-week to 88-week trial endpoints, long-term outcome data — particularly across diverse populations, and particularly outside of patients with diabetes — is still accumulating. Patients should expect that the published understanding of these medications will continue to evolve over the next decade.
Our methodology is built around root-cause metabolic optimization. The reason a patient is gaining weight in their late 30s, 40s, 50s, or 60s is almost never because they lack appetite suppression. It is almost always because the underlying metabolic machinery has shifted — insulin resistance has crept in, hormones have declined, thyroid function has dulled, cortisol has stayed elevated for years.
Suppressing appetite while leaving those underlying drivers untouched produces fast weight loss, often with lean-mass cost, and frequently with regain on cessation. The patient who wants sustainable body composition needs the underlying drivers addressed. That is the work we do.
This is a clinical philosophy, not a moral position on GLPs. We refer patients who want GLP-1 medications to their primary care physician or endocrinology team. They are appropriate for some patients in some contexts, and a thoughtful PCP or endocrinologist can manage them well. Our role is the other path — the methodology, not the medication.
Every weight-management patient at THE WELLNESS CO. enters through the CLARITY clinical methodology — the same biomarker-driven, continuously-adapting framework that anchors every hormone-, peptide-, and metabolic-optimization protocol we deliver.
A comprehensive panel of forty-two biomarkers across ten body systems, including the markers most often missed by annual physicals: fasting insulin, HOMA-IR, full thyroid (TSH, Free T3, Free T4, Reverse T3), sex hormones, cortisol, DHEA-S, hs-CRP, and apolipoprotein measures. Dawn Philp, FNP-BC personally reviews every panel.
To be clear: GLP-1 medications are appropriate for some patients. Patients with type 2 diabetes who need both glucose control and weight reduction. Patients with significant obesity (BMI ≥ 35) where lifestyle and standard pharmacology have not produced sufficient response and surgical alternatives carry their own risks. Patients with documented cardiovascular indications where the GLP-1 class has shown benefit.
These are situations where the risk-benefit calculation can favor GLP-1 therapy. They are also situations where a primary care physician or endocrinologist — not a wellness optimization clinic — is the appropriate prescriber. The work involves managing GI tolerability, monitoring for adverse events, coordinating with other care, and making the medication-vs-discontinue decision over time.
If that is your situation, we are not the right clinic to manage your care. If your situation is the more common one — declining metabolic function in your 40s, 50s, or 60s, despite a clean lifestyle, with the underlying hormonal and insulin patterns that produce that decline — the CLARITY methodology is what we built.
If you came here researching whether GLP-1 medications are right for you, the answer is: have the conversation with a physician who knows your full case and can co-manage with you long-term.
If you came here looking for an alternative to GLP-1 medications — an approach that addresses the metabolic shift rather than the appetite signal — that is what THE WELLNESS CO. does. You can upload existing bloodwork through our free lab review service and our clinical team will tell you what your panel is actually showing through the CLARITY framework. Or you can book a consultation directly.
Either way: the most important step is reading your own data clearly before any medication enters the picture.
Upload your recent bloodwork. Our clinical team interprets it through the CLARITY framework and tells you what your insulin, thyroid, hormones, and metabolic markers are actually saying. Free, no commitment.
Get Your Free Lab Review →One consultation. Your biomarkers map the protocol.
Book Your Consultation